What is the prevalence of multiple sclerosis (MS)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 25, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Prevalence of Multiple Sclerosis

The global prevalence of multiple sclerosis is approximately 35.9 per 100,000 population, with an estimated 2.8 million people living with MS worldwide, though this varies dramatically by geographic region. 1

Global and Regional Prevalence

  • In the United States, approximately 900,000 people are affected by MS, representing one of the highest prevalence regions globally. 2

  • High-prevalence regions (North America and Europe) demonstrate rates exceeding 100 per 100,000 inhabitants, while low-prevalence regions (Eastern Asia and sub-Saharan Africa) show rates as low as 2 per 100,000 population. 3

  • France specifically shows a prevalence of 94.7 per 100,000 population, with higher rates concentrated in the northern and eastern regions of the country. 3

  • The worldwide prevalence ranges from 5 to 300 per 100,000 people, with a clear latitude gradient showing increasing prevalence at higher latitudes away from the equator. 2

Temporal Trends

  • MS prevalence has increased in every world region since 2013, suggesting either true increases in disease occurrence or improved diagnostic capabilities and case ascertainment. 1

  • The incidence of MS is rising worldwide, along with the socioeconomic burden of the disease, though the underlying mechanisms driving this increase remain incompletely understood. 4

  • The pooled incidence rate across 75 reporting countries is 2.1 per 100,000 persons per year. 1

Demographic Patterns

  • Females are twice as likely to develop MS as males globally, with the female-to-male ratio approaching 3:1 in recent decades. 2, 1

  • In France and several other countries, the gender ratio for MS incidence increased from 2:1 to 3:1 between the 1950s and 2000s, but this shift occurred only for the relapsing-remitting form. 3

  • The mean age of diagnosis is 32 years, with typical presentation occurring in young adults aged 20-30 years. 2, 1

Important Caveats

  • Significant gaps in prevalence estimates persist across many regions, particularly in low- and middle-income countries where surveillance systems may be inadequate. 1

  • Prevalence estimates vary considerably based on diagnostic criteria used, case ascertainment methods, and healthcare access, making direct comparisons between studies and time periods challenging. 3

  • The disease shows ethnic variation, with higher rates in populations of European ancestry and lower rates in Asian and sub-Saharan African populations, though migration studies suggest environmental factors play a substantial role beyond genetics alone. 5, 3

References

Research

Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition.

Multiple sclerosis (Houndmills, Basingstoke, England), 2020

Research

Epidemiology of multiple sclerosis.

Revue neurologique, 2016

Research

Multiple sclerosis - a review.

European journal of neurology, 2019

Guideline

Multiple Sclerosis Pathogenesis and Risk Factors

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Related Questions

What medical conditions are people with Multiple Sclerosis (MS) prone to?
Is oral Minoxidil (minoxidil) safe for patients with Multiple Sclerosis (MS)?
Does Multiple Sclerosis (MS) cause difficulty recovering from influenza (flu)?
What is the most likely diagnosis for a 30-year-old female with acute facial pain on teeth brushing, unresponsive to analgesics (pain medications), and internuclear ophthalmoplegia, with abnormal Magnetic Resonance Imaging (MRI) findings?
What are the treatment options for active multiple sclerosis (MS)?
Is a Left T4, T5 Intercostal Nerve block (injection, anesthetic and/or steroid; intercostal nerve, single) medically necessary for a patient with intercostal neuralgia and other specified mononeuropathies (G58.8) who has failed conservative management with medications like Tizanidine, lidocaine (5% patch), ibuprofen, and extra strength Tylenol (acetaminophen)?
Can permethrin be used on the face?
What is the first-line treatment for a 13-year-old female with chronic diarrhea and altered bowel habits, diagnosed with transmural inflammation on colonoscopy, suggestive of Crohn's disease (inflammatory bowel disease)?
What should the admitting diagnosis be for a patient with septic shock who has chosen palliative care?
What is the next most appropriate investigation for a patient with severe headache, blurry vision, and increased intracranial pressure, with a history of postpartum cardiomyopathy and chronic changes on CT (Computed Tomography) scan?
Is Ruxience (rituximab) and IVIG Privigen (immune globulin intravenous) medically indicated for a patient with a history of impaired renal function who is scheduled for a kidney transplant and is at risk for antibody-mediated rejection due to the presence of strong Angiotensin II Type 1 Receptor Antibodies (AT1R Ab)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.